Dr. Michael Spartalis is an Attending Cardiologist, Certified Electrophysiology Specialist, and Certified Cardiac Device Specialist. Currently, an Academic Scholar (Adjunct Lecturer) at the 3rd Department of Cardiology, National and Kapodistrian University of Athens, Clinical Scholar at Harvard Medical School, Associate Editor of European Heart Journal Case Reports and an Expert on medical devices at the European Commission.
His work focuses on cardiovascular medicine, cardiac electrophysiology, device therapy, and antiplatelet therapy. He currently works on evidence regarding the beneficial therapy with colchicine for atherosclerosis via anti-inflammation and decrease in hypertriglyceridemia. He is also Co-Investigator on three large-scale randomized multicenter trials.
He has published in leading journals, including the New England Journal of Medicine, Circulation, Journal of Heart and Lung Transplantation, and Annals of Surgery. His research activity is documented by the production of 107 published articles in high-impact medical journals, all indexed in PubMed.
Among notable honors, he was awarded: Fellow of the European Society of Cardiology (FESC), as a symbol of Scientific Excellence from the European Society of Cardiology in 2017, Fellow of the American College of Cardiology (FACC) Designation from the American College of Cardiology in 2018, Fellow of the European Heart Rhythm Association (FEHRA) honorary recognition from the European Heart Rhythm Association in 2019.
He holds an MD from National and Kapodistrian University of Athens, Medical School, a MSc in Thrombosis, Hemorrhage and Transfusion medicine from National and Kapodistrian University of Athens, Medical School, a MHCM from Conservatoire National des Arts et Métiers, and a Master in Interventional Electrophysiology from Università Vita-Salute San Raffaele. Most recently, he completed the Oxford's Leadership Program.